Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

workflow

Roche - Basel

Roche’s Erivedge authorised in UK

Available for skin cancer patients through Cancer Drugs Fund

Roche's Perjeta pertuzumab

Roche’s breast cancer drug too expensive for NHS use

But pharma company says UK Government dithering on Perjeta patient access scheme

- PMLiVE

Roche loses Herceptin patents in India

Government says pharma company did not follow correct filing procedure

Roche - Basel

Roche cuts cost of drug to prevent blindness in HIV patients

Will improve access to Valcyte in developing nations

Roche - Basel

New cancer drugs help drive Roche in first half

Perjeta, Kadcyla and Zelboraf support company growth

Roche - Basel

Roche antibody tops Rituxan in blood cancer CLL

Obinutuzumab on course for leukaemia approval by year-end

- PMLiVE

NICE demands more data from Roche for MabThera in rare autoimmune disease

Unable to recommend expanding drug’s indication to include vasculitis

- PMLiVE

Analysts question value of rumoured $20bn Roche bid for Alexion

Shares in orphan drug specialist slide back after earlier surge

Roche - Basel

Roche wins conditional EU approval for cancer drug Erivedge

Can market it for advanced basal cell carcinoma but must provide more safety data

Roche - Basel

Late-stage blow to Roche’s diabetes ambitions

Halts development of aleglitazar on safety and efficacy concerns

Digital research in Asia

Director Marc Yates uses findings from a study conducted in six markets in Asia to explore how digital channels are being utilised by consumers and look at the digital opportunities...

Research Partnership

Roche - Basel

Roche’s blood cancer antibody wins priority review in US

Obinutuzumab is fast-tracked by FDA in treatment of chronic lymphocytic leukaemia

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links